FDA OKs New Drug for Lung Cancer With c-Met Overexpression

(MedPage Today) — The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, locally advanced, or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein…

Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/115586

Author :

Publish date : 2025-05-14 20:48:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

FDA OKs New Drug for Lung Cancer With c-Met Overexpression

First Oral Therapy for Rare Adrenal Gland Tumors Gets Green Light From FDA

Mucus-Plugged Airways Linked to COPD Outcomes

Related Posts

Mum of boy with PPFIBP1 gene says finding others gave her ‘strength’

Novel Anticoagulant Flops for Staving Off Graft Thrombosis in Dialysis Patients

Home Testing Doubles Cervical Cancer Screening in Safety-Net Population

Infectious Disease Docs Slam New COVID Vaccine Recommendations

Some Psych Meds Tied to Higher Future Risk of ALS

Sibeprenlimab Halves uPCR in IgA Nephropathy Trial

Mum of boy with PPFIBP1 gene says finding others gave her ‘strength’

Novel Anticoagulant Flops for Staving Off Graft Thrombosis in Dialysis Patients

Home Testing Doubles Cervical Cancer Screening in Safety-Net Population

Infectious Disease Docs Slam New COVID Vaccine Recommendations

Some Psych Meds Tied to Higher Future Risk of ALS

Sibeprenlimab Halves uPCR in IgA Nephropathy Trial

Nefecon Shows IgAN Benefits Regardless of Baseline eGFR

Why Choose Second Opinions? Risky Cancer Searches; 18 Months to Live, 20 Years Later

Categories

Archives